Inducible Cre mice.
The Cre/lox site-specific recombination system has emerged as an important tool for the generation of conditional somatic mouse mutants. This method allows one to control gene activity in space and time in almost any tissue of the mouse, thus opening new avenues for studying gene function and for establishing sophisticated animal models of human diseases. A major technical advance in terms of in vivo inducibility was the development of ligand-dependent Cre recombinases that can be activated by administration of tamoxifen to the animal. Here we describe how tamoxifen-dependent Cre recombinases, so-called CreER recombinases, work and how they can be used to generate time- and tissue-specific mouse mutants. The focus will be on the CreER(T2) recombinase, which is currently the most successful CreER version. We will give an overview of available CreER(T2) transgenic mouse lines and present protocols that detail the generation of experimental mice for inducible gene knockout studies, the induction of recombination by tamoxifen treatment, and the analysis of the quality and quantity of recombination by reporter gene and target gene studies. Most of the protocols can also be used as general guidelines for the generation and characterization of Cre/lox-mediated genome modifications in mice.
Feil
Susanne
S
Interfakultäres Institut für Biochemie, Universität Tübingen, , Tübingen, Germany.
Valtcheva
Nadejda
N
Feil
Robert
R
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D055786:Gene Knockout Techniques / Q000379:methods*; D019426:Integrases / Q000502:physiology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic / Q000502:physiology*; D013629:Tamoxifen / Q000494:pharmacology*
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; C045073:Cre recombinase; D019426:Integrases